Pluristem Therapeutics (NASDAQ:PSTI) has been assigned a $3.00 price target by analysts at Maxim Group in a note issued to investors on Tuesday. The firm presently has a “buy” rating on the biotechnology company’s stock. Maxim Group’s price target points to a potential upside of 185.71% from the stock’s current price.
Separately, HC Wainwright set a $4.00 target price on shares of Pluristem Therapeutics and gave the stock a “buy” rating in a report on Monday, November 12th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $3.25.
PSTI opened at $1.05 on Tuesday. Pluristem Therapeutics has a twelve month low of $1.02 and a twelve month high of $1.65. The stock has a market capitalization of $125.07 million, a PE ratio of -4.20 and a beta of 0.47.
Pluristem Therapeutics (NASDAQ:PSTI) last posted its earnings results on Thursday, November 8th. The biotechnology company reported ($0.08) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.09) by $0.01. On average, research analysts expect that Pluristem Therapeutics will post -0.31 earnings per share for the current year.
A number of hedge funds and other institutional investors have recently modified their holdings of PSTI. ARK Investment Management LLC lifted its position in Pluristem Therapeutics by 101.3% during the 3rd quarter. ARK Investment Management LLC now owns 2,892,231 shares of the biotechnology company’s stock worth $3,760,000 after buying an additional 1,455,730 shares in the last quarter. B. Riley Financial Inc. acquired a new position in Pluristem Therapeutics during the 3rd quarter worth about $320,000. Virtu Financial LLC lifted its position in Pluristem Therapeutics by 964.8% during the 3rd quarter. Virtu Financial LLC now owns 174,174 shares of the biotechnology company’s stock worth $523,000 after buying an additional 157,816 shares in the last quarter. Renaissance Technologies LLC lifted its position in Pluristem Therapeutics by 5.8% during the 3rd quarter. Renaissance Technologies LLC now owns 1,331,100 shares of the biotechnology company’s stock worth $1,730,000 after buying an additional 72,600 shares in the last quarter. Finally, Jane Street Group LLC lifted its position in Pluristem Therapeutics by 337.4% during the 3rd quarter. Jane Street Group LLC now owns 94,023 shares of the biotechnology company’s stock worth $122,000 after buying an additional 72,526 shares in the last quarter. Institutional investors and hedge funds own 5.23% of the company’s stock.
About Pluristem Therapeutics
Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.
Read More: Rule of 72
Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.